This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
HannoP.M.BurksD.A.ClemensJ.Q.; Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol.2011; 185(6): 2162–2170.
2.
ButrickC.W.Interstitial cystitis/bladder pain syndrome: Management of the pain disorder: A urogynecology perspective. Urol Clin North Am.2012; 39(3): 377–387.
FallM.OberpenningF.PeekerR.Treatment of bladder pain syndrome/interstitial cystitis 2008: Can we make some evidence-based decisions?Eur Urol.2008; 54(1): 65–75.
5.
FosterH.E.JrHannoP.M.NickelJ.C.; Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. J Urol.2010; 183(5): 1853–1858.
6.
van OphovenA.HertleL.Long-term results of amitriptyline treatment for interstitial cystitis. J Urol.2005; 174(5): 1837–1840.
7.
van OphovenA.PokupicS.HeineckeA.HertleL.A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol.2004; 172(2): 533–536.
